G protein-coupled receptors (GPCRs) are an important class of drug targets. At present, more than 40% of drugs on the market play a therapeutic role by acting on GPCRs. There are about 800-1000 GPCRs in the human body, and it is found that the new role of GPCRs in major diseases can provide new drug targets or new methods for disease treatment. Multiple sclerosis (MS) is an autoimmune disease related to the nervous system. It is the cause of disability after trauma in young and middle-aged people. At present, there is still no effective therapeutic drug, and it has "cannot die of cancer." Known as. When studying the relationship between GPCR and the disease, Wei Wei, a doctoral student of Tongji University, and Du Changsheng, an associate professor, found that there is a class of GPCR (A2B adenosine receptor, A2BAR) expression in EAE mice, which is an animal model of MS, significantly increased with the disease process. A2BAR has a weak binding ability to its ligand adenosine, and generally requires a high concentration of adenosine to activate. In the stress state such as inflammation and hypoxia, the adenosine level in the body will greatly increase and activate A2BAR. Using A2BAR knockout mice and A2BAR specific antagonists, the study found that blocking A2BAR signal transduction can effectively inhibit the disease process. Further research found that A2BAR located on the surface of antigen-presenting dendritic cells (DC) is essential for the secretion of inflammatory factor IL-6. Inhibiting the secretion of IL-6 stimulated by A2BAR can effectively inhibit the differentiation of downstream T effector cells. So as to ease the occurrence of disease. Mechanism research found that A2BAR mainly stimulates IL-6 secretion by activating PLC-PKC and p38 MAPK two pathways. More interestingly, A2BAR is also up-regulated in the blood cells of MS patients, further suggesting its relevance to disease. This study suggests that A2BAR can be used as a new target for the development of autoimmune diseases. The research results were published online in the Journal of Immunology on December 5. This research work was completed under the guidance of Researcher Xie Xin. Researcher Xie Xin is the project leader of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, deputy director of the National Center for New Drug Screening, an adjunct professor at the School of Life Science and Technology of Tongji University, and a doctoral supervisor. Mainly engaged in the research of new drug discovery and mechanism based on GPCR, as well as the research of small molecule compounds regulating the fate of stem cells. The research team recently reported that anti-asthma drugs targeting cysteine ​​leukotriene receptors can be used to treat MS (Journal of Immunology. 2011; 187 (5): 2336-45). The MS patient samples in this research work were collected and provided by the team of Professor Wu Zhiying from Huashan Hospital. This research work was supported by the National Natural Science Foundation of China, the Ministry of Science and Technology and the Shanghai Science and Technology Commission Empty Pet Bottles,Body Wash Bottles,Body Wash Pump Bottle,Body Wash Dispenser Bottles GuangZhou ShenRuo Plastic Manfacturing CO.,Ltd , https://www.cnbottle.com